BioArctic AB (LTS:0RV2) Cyclically Adjusted Revenue per Share: kr6.15 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RV2 BioArctic AB LTS:0RV2
75 GF Score
Price kr312.00
GF Value kr485.11
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is BioArctic AB Cyclically Adjusted Revenue per Share?

BioArctic AB LTS:0RV2 +1.60% 75 Cyclically Adjusted Revenue per Share is kr6.15 as of Mar. 2026. GuruFocus rates LTS:0RV2 with a GF Score™ of 75/100 and a GF Value™ of kr485.11 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioArctic AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr4.924. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr6.15 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-25), BioArctic AB's current stock price is kr312.00. BioArctic AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr6.15. BioArctic AB's Cyclically Adjusted PS Ratio of today is 50.73.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of BioArctic AB was 57.87. The lowest was 49.16. And the median was 52.55.


BioArctic AB  (LTS:0RV2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioArctic AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=312.00/6.15
=50.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of BioArctic AB was 57.87. The lowest was 49.16. And the median was 52.55.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioArctic AB Cyclically Adjusted Revenue per Share Related Terms


BioArctic AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioArctic AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioArctic AB Cyclically Adjusted Revenue per Share Chart

BioArctic AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioArctic AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.15

LTS:0RV2 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BioArctic AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioArctic AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Cyclically Adjusted PS Ratio falls into.


LTS:0RV2
75GF Score
BioArctic AB LTS:0RV2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioArctic AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioArctic AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.924/133.5600*133.5600
=4.924

Current CPI (Mar. 2026) = 133.5600.

BioArctic AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 100.276 0.000
201609 0.013 101.138 0.017
201612 1.072 102.022 1.403
201703 0.297 102.022 0.389
201706 0.364 102.752 0.473
201709 0.358 103.279 0.463
201712 0.579 103.793 0.745
201803 0.611 103.962 0.785
201806 0.613 104.875 0.781
201809 1.068 105.679 1.350
201812 5.750 105.912 7.251
201903 0.720 105.886 0.908
201906 1.946 106.742 2.435
201909 0.234 107.214 0.292
201912 0.300 107.766 0.372
202003 0.412 106.563 0.516
202006 0.080 107.498 0.099
202009 0.120 107.635 0.149
202012 0.094 108.296 0.116
202103 0.081 108.360 0.100
202106 0.082 108.928 0.101
202109 0.045 110.338 0.054
202112 0.052 112.486 0.062
202203 0.042 114.825 0.049
202206 0.048 118.384 0.054
202209 2.457 122.296 2.683
202212 0.023 126.365 0.024
202303 4.432 127.042 4.659
202306 0.031 129.407 0.032
202309 2.357 130.224 2.417
202312 0.125 131.912 0.127
202403 0.336 132.205 0.339
202406 0.564 132.716 0.568
202409 0.867 132.304 0.875
202412 1.145 132.987 1.150
202503 14.557 132.825 14.638
202506 4.429 133.699 4.424
202509 1.505 133.480 1.506
202512 2.076 133.390 2.079
202603 4.924 133.560 4.924

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr6.15 mean?
BioArctic AB (LTS:0RV2) has a Cyclically Adjusted Revenue per Share of kr6.15 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioArctic AB and its competitors.
Is BioArctic AB's Cyclically Adjusted Revenue per Share too high?
BioArctic AB's current Cyclically Adjusted Revenue per Share is kr6.15. Overall, BioArctic AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
BioArctic AB's Cyclically Adjusted Revenue per Share of kr6.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioArctic AB and its competitors. BioArctic AB's current Cyclically Adjusted Revenue per Share is kr6.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Significantly Undervalued. The stock's GF Value™ is kr485.11, compared to a current price of kr312.00 — trading 35.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr6.15. BioArctic AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current Cyclically Adjusted Revenue per Share is kr6.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (LTS:0RV2) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of kr312.00 is trading 35.7% below its estimated GF Value™ of kr485.11. GuruFocus considers BioArctic AB to be Significantly Undervalued.

Key valuation signals for LTS:0RV2:

  • Cyclically Adjusted Revenue per Share: kr6.15
  • GF Value™: kr485.11 vs. price of kr312.00 (35.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
75GF Score

Get the complete analysis for LTS:0RV2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr312.00
Price
kr485.11
GF Value